Skip to main content
. Author manuscript; available in PMC: 2021 Sep 3.
Published in final edited form as: Cancer Res. 2021 Jun 22;81(17):4581–4593. doi: 10.1158/0008-5472.CAN-20-3323

Figure 6. Nelfinavir impairs the homeostasis of lipid composition in lipid-rich membranes and lipid droplets.

Figure 6

A) Relative contents of fatty acids (FA) in membrane phosphatidylcholines (PC) upon treatment with 40 μM nelfinavir for 6h. SFA, saturated fatty acids; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids. B) Relative content of FA in membrane phosphatidylethanolamines (PE) upon treatment with 40 μM nelfinavir for 6h. C) Cholesterol esters (CE) and D) triacylglycerols (TAG) in lipid droplets upon treatment with 40 μM nelfinavir for 6h expressed as a ratio between CE or TAG to membrane PC. Data show the mean of a representative experiment ± SEM and statistically significant differences are marked with *** at p<0.001 and * at p<0.05. E) Principal Component Analysis (PCA) plot separating control and 20 μM nelfinavir-treated AMO-1 cells for 6h, based on their lipid composition. F) Lipid composition separating untreated and nelfinavir-treated AMO-1 cells, where the number of double bonds is indicated for the most differentiated lipids. Note that the main separators are PC containing 0 or 1 double bonds. G-H) Heat-maps for PC/PE and phosphatidylinositol (PI) species. Data show results of five replicates.